Entity

Time filter

Source Type

New York, NY, United States

Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2011-ITN | Award Amount: 4.31M | Year: 2012

The most prevalent chronic inflammatory diseases of humans are complex disorders of multifactorial aetiology influenced by genes, the environment and their interactions. Periodontitis (PD) and rheumatoid arthritis (RA) are two such chronic inflammatory diseases associated with significant morbidity and mortality, and have recently shown to have a bi-directional association. Moreover, the prevalence of both increases substantially with age, and given both the Europe-wide ageing population and the impact of both diseases upon the economy, health and quality of life, it is clear that novel and more cost effective approaches to management are urgently required. A key research goal of this project is to improve understanding of the pathogenesis of RA and PD and their inter-relationships, through the study of common risk factors linked to the activation of host and bacterial derived protein citrullination, which subsequently generates pro-inflammatory auto-antigens in the joints and periodontal tissues. Our vision is that enhanced biological understanding in this area will inform the future development of new approaches to disease prevention, early diagnosis and novel therapies. RAPID aims to provide a significant contribution to this by establishing a first class, dynamic training network of 12 partners and 5 associated partners for early career researchers who will be able to advance chronic inflammatory disease research by working across sectors and disciplines. The network is an interdisciplinary cooperative of medical and dental clinicians, epidemiologists, bio-scientists, industrial scientists, media and commercialization specialists. The aim of the Training Programme is to increase the knowledge base and experience of trainees in the different research areas and to develop their transferable skills for future careers in industry or academia, whilst advancing the field through new discovery.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 42.29K | Year: 2013

Beating cancer requires a treatment that kills cancer cells but leaves normal tissue unharmed. While this seems simple enough it is actually very difficult because cancer cells look so much like normal cells when it comes to treating with anti-cancer drugs. The drugs that are available to treat cancer all aim to target cancer cells in preference to normal cells but how good they are at doing this will depend on how toxic they are to the cancer of that particular patient. If a particular cancer is very sensitive to a drug then it can be used at lower doses thus minimizing nasty side effects. Similarly if the cancer is very resistant to a drug then using it will only damage normal tissue and make the situation worse. The currently funded project aims to develop a clever diagnostic assay that will tell the clincians which of the available drugs will be most effective for each patient thus personalising the treatment of cancer and so helping those who are afflicted with this terrible condition.


Imagen Biotech | Entity website

About Immunohistochemical labeling of cone photoreceptor cells from a human retina. Image courtesy of Robert Mullins, PhD, University of Iowa ...


Imagen Biotech | Entity website

Our Team Matthew Feinsod, MD, Co-founder, Chief Medical Officer Matthew Feinsod, MD, was SVP of Strategy and Product Development at Eyetech Pharmaceuticals where he spent five years in a variety of functions helping to develop Macugen and preclinical programs. Prior to joining Eyetech, Matt served as medical officer at the U ...

Discover hidden collaborations